Black Diamond Therapeutics, Inc. (BDTX)
| Market Cap | 102.86M-55.0% |
| Revenue (ttm) | 0 |
| Net Income | -42.55M |
| EPS | -0.75 |
| Shares Out | 57.30M |
| PE Ratio | n/a |
| Forward PE | -1.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 223,723 |
| Open | 1.80 |
| Previous Close | 1.83 |
| Day's Range | 1.77 - 1.81 |
| 52-Week Range | 1.60 - 4.94 |
| Beta | 3.33 |
| Analysts | Strong Buy |
| Price Target | 10.00(+457.10%) |
| Earnings Date | Nov 5, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About BDTX
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
$BDTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BDTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BDTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BDTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BDTX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Collaborative arrangement, contingent milestone payments | $710.00M | 91.03% |
| Collaborative arrangement, upfront payment | $70.00M | 8.97% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BDTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BDTX from public contracts
Source: USAspending.gov
BDTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BDTX’s recent data — informational, not investment advice